Abstract
The Tat protein of the human immunodeficiency virus type 1 promotes survival and growth and inhibits apoptosis of different cell types. These effects of Tat are attributed to the induction of bcl-2 gene expression. In this study we show that the blocking of both intracellular and extracellular Tat correlates with a decrease of bcl-2 transcripts, leading in vitro to a lower growth rate and attenuation of the transformed phenotype and in vivo to a reduced angiogenic and oncogenic activity of Tat-expressing cells. These results support the notion that bcl-2 is an effector of Tat-induced angiogenesis and oncogenesis and indicate that the blocking of Tat functions by immunoprophylactic, pharmacological, and gene therapy approaches may help to control oncogenesis during AIDS.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies / pharmacology
-
Antisense Elements (Genetics)
-
Apoptosis
-
Carcinogenicity Tests
-
Distamycins / pharmacology
-
Down-Regulation
-
Gene Expression Regulation, Viral / drug effects
-
Gene Products, tat / antagonists & inhibitors
-
Gene Products, tat / genetics
-
Gene Products, tat / physiology*
-
HIV-1*
-
Mice
-
Mice, Inbred BALB C
-
Mice, Nude
-
Mice, Transgenic
-
Neovascularization, Pathologic*
-
Proto-Oncogene Proteins c-bcl-2 / biosynthesis*
-
Proto-Oncogene Proteins c-bcl-2 / genetics
-
RNA, Messenger / analysis
-
Tumor Cells, Cultured
-
tat Gene Products, Human Immunodeficiency Virus
Substances
-
Antibodies
-
Antisense Elements (Genetics)
-
Distamycins
-
Gene Products, tat
-
PNU 153429
-
Proto-Oncogene Proteins c-bcl-2
-
RNA, Messenger
-
tat Gene Products, Human Immunodeficiency Virus